<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="899">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149456</url>
  </required_header>
  <id_info>
    <org_study_id>8373</org_study_id>
    <nct_id>NCT05149456</nct_id>
  </id_info>
  <brief_title>Peripheral Artery Occlusive Disease (PAOD) in Women Hospitalized for Type 1 Myocardial Infarction in Intensive Cardiology Care</brief_title>
  <acronym>AOMI</acronym>
  <official_title>Study of the Prevalence of Peripheral Artery Occlusive Disease (PAOD) in Women Hospitalized for Type 1 Myocardial Infarction in Intensive Cardiology Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cardiovascular risk of women has been the subject of particular interest in recent years,&#xD;
      in the world, in particular under the impetus of Cardiology companies, with more and more&#xD;
      work focusing on the specificities of these diseases in women as well as differences in terms&#xD;
      of management and prognosis with a literature mainly based on American data and which focuses&#xD;
      particularly on ischemic heart disease.&#xD;
&#xD;
      The expected results are to have a prevalence of PAOD in an Alsatian cohort, most of the data&#xD;
      we currently have from American data, with analysis of the impact of specific and&#xD;
      non-specific risk factors in this cohort and their weight in PAOD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the prevalence of peripheral artery occlusive disease (PAOD)</measure>
    <time_frame>Files analysed retrospectively from January 01, 2021 to Jun 30, 2021 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>PAOD - Peripheral Arterial Occlusive Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult woman hospitalized in an Intensive Cardiology Unit (ICU) at the HUS for a type 1&#xD;
        myocardial infarction confirmed according to the criteria of the fourth universal&#xD;
        definition of the ESC between 01/01/2021 to 30/06/2021 inclusive&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult woman (≥18 years old)&#xD;
&#xD;
          -  Patient hospitalized in an Intensive Cardiology Unit (ICU) at the HUS for a type 1&#xD;
             myocardial infarction confirmed according to the criteria of the fourth universal&#xD;
             definition of the ESC between 01/01/2021 to 30/06/2021 inclusive&#xD;
&#xD;
          -  Patient who did not express her opposition to the reuse of her data for scientific&#xD;
             research purposes.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient who expressed her opposition to participating in the study&#xD;
&#xD;
          -  Impossibility of providing the subject with enlightened information (difficulties in&#xD;
             understanding the subject, MMS &lt;20/30…)&#xD;
&#xD;
          -  Non-type 1 or unconfirmed myocardial infarction&#xD;
&#xD;
          -  Unstable or refractory shock state at the time of the echodoppler examination&#xD;
&#xD;
          -  Complication of the coronary angiography approach, in the case of femoral approach&#xD;
             only, requiring surgical management.&#xD;
&#xD;
          -  Patient under curatorship, guardianship or judicial safeguard.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique STEPHAN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies VASC-HTA-Pharmacologie Clinique - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique STEPHAN, MD, PhD</last_name>
    <phone>33 3 69 55 09 52</phone>
    <email>dominique.stephan@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service des Maladies VASC-HTA-Pharmacologie Clinique - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique STEPHAN, MD, PhD</last_name>
      <phone>33 3 69 55 09 52</phone>
      <email>dominique.stephan@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique STEPHAN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marjolaine TALBOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SEVERAC, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Occlusive Disease</keyword>
  <keyword>PAOD</keyword>
  <keyword>Cardiovascular risk factors</keyword>
  <keyword>Myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

